Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
3 September 2018 |
Main ID: |
EUCTR2008-001597-33-NL |
Date of registration:
|
29/05/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the course of the disease. - The TIKI study : Treatment with or without IVIG in Kids with acute ITP
|
Scientific title:
|
Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the course of the disease. - The TIKI study : Treatment with or without IVIG in Kids with acute ITP |
Date of first enrolment:
|
18/06/2009 |
Target sample size:
|
300 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001597-33 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: careful observation without medication
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Netherlands
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: General inclusion criteria - Children aged 3 months -16 years, presenting to a pediatrician with newly diagnosed acute ITP and - Platelet count < 20 x 10 9 /L and - Bleeding tendency < grade 4 (Buchanan) and - no prior immunomodulating treatment within 4 weeks before diagnosis and - signed informed consent by parents and/ or patients
Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: A patient presenting with any of the following criteria will not be included in the study:
General exclusion criteria - clinical features that are not compatible with the diagnosis of acute ITP, for example: presence of other auto-immune phenomena, organomegaly, other cytopenias besides thrombocytopenia or features susceptible for infectious disease like hepatitis, Epstein-Barr virus or HIV - immunomodulating treatment (IVIG, corticosteroids) within 4 weeks before diagnosis - history of allergic reactions against human plasma, plasma products or intravenous immunoglobulin - Severe or life threatening bleeding at presentation: grade 4 or 5 (Buchanan) - No informed consent
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Acute Idiopathic Thrombocytopenic Purpura (ITP) in children MedDRA version: 14.1
Level: LLT
Classification code 10023095
Term: ITP
System Organ Class: 10005329 - Blood and lymphatic system disorders
|
Intervention(s)
|
Trade Name: Nanogam Pharmaceutical Form: Solution for infusion Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-
|
Primary Outcome(s)
|
Secondary Objective: Secondary objectives are:
1. To evaluate the clinical parameters during the course of the disease, eg: bleeding score and time between onset of symptoms and recovery of platelet numbers. 2. Comparing the HRQoL in parents and patients with acute ITP who did and did not have IVIG and in those that do and do not develop chronic ITP.
3. Estimation of variability of biological parameters of the immune system of the patient that are supposed to be involved in the differences in outcome between acute vs. chronic disease as well as between response on IVIG treatment vs. non response. These include: A) the genetic polymorphisms of the activating and inhibiting IgG-Fc receptor and other inhibiting immune receptors. B) Immunoglobulin glycosylation variability within the platelet auto antibodies and its changes during time, as well as the changes due to IVIG treatment. C) Quantity and function of regulatory T cells.
|
Main Objective: The primary objective is to investigate the hypothesis that early IVIG treatment in children with newly diagnosed acute ITP reduces the risk of development of chronic disease.
|
Primary end point(s): Primary study endpoint is development of chronic ITP, defined by a platelet count of < 150 x 10^9/l six months after diagnosis.
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|